SHIFT

Systolic Heart failure treatment with the lf inhibitor ivabradine Trial

Skip to content
  • Home
  • SHIFT
  • IVABRADINE
  • HEART RATE & HEART FAILURE
  • NEWSROOM
  • RESOURCES
  • CONTACT US
Home > newsroom > Press releases

Press releases

PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
PROCORALAN REDUCES THE RISK OF DEATH AND HOSPITALIZATION FOR HEART FAILURE IN CHRONIC HEART FAILURE PATIENTS BY MORE THAN A QUARTER
SHIFT Study: Backgrounder
Chronic heart Failure: Backgrounder
This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information. This site is published and updated by the SHIFT study investigators-©2021 SHIFT. All rights reserved. Report a side-effect with a drug.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more